Clinical trial

A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)

NCT00449033

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-02-01

PhasePHASE3

Study timeline

Study start (unknown)2007-02-01Date precision: month

Registry last updated2015-04-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Carcinoma, Non-Small-Cell Lungunresolved

Interventions

Sorafenib (Nexavar, BAY43-9006)DRUG

PlaceboDRUG

GemcitabineDRUG · verified · RxNorm: gemcitabine

CisplatinDRUG · verified · RxNorm: cisplatin

Sponsors & collaborators

Bayerlead sponsor

Mapped research locations

São PauloSão Paulo, Brazil4 BudapestHungary2 ShanghaiChina2 ViennaAustria2 HangzhouZhejiang, China2 Porto AlegreRio Grande do Sul, Brazil2 GrenobleFrance2 MadridMadrid, Spain2 ParisFrance1 MontrealQuebec, Canada1 MilanItaly1 GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00449033 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.